TearClear Announces Initiation of TC-002 Latanoprost Ophthalmic Solution Phase 3 Trial

UF startup TearClear has announced the TC-002 phase 3 trial has been successfully initiated. TearClear’s phase 3 trial (CLEAR Study) is a prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of TC-002 ophthalmic solution (TearClear Preservative-Free Latanoprost Ophthalmic Solution 0.005%) compared to marketed Latanoprost ophthalmic solution 0.005%.

TearClear, located at UF Innovate | Accelerate at Sid Martin Biotech, has developed a novel investigational platform through which topical ophthalmic solutions are preserved in a patient-friendly multi-dose bottle but are delivered to the ocular surface as preservative-free.

Read more about TearClear Announces Initiation of TC-002 Latanoprost Ophthalmic Solution Phase 3 Trial.